In addition, the mechanism(s) conferring resistance of HNSCC against agents targeting the EGFR are ill-defined [8, 9], and the required agents are expensive and often show a suboptimal pharmacodynamic profile. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.